# EDGAR Filing Document

**Accession Number:** 0001359931
**File Stem:** 0001213900-23-018541
**Filing Date:** 2023-3
**Character Count:** 23227
**Document Hash:** 08f82c48466a0af497490019858b408e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-018541.hdr.sgml**: 20230308

**ACCESSION NUMBER**: 0001213900-23-018541

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20230308

**DATE AS OF CHANGE**: 20230308

**EFFECTIVENESS DATE**: 20230308

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Protara Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001359931
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 204580525
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270354
- **FILM NUMBER:** 23716238

**BUSINESS ADDRESS:**
- **STREET 1:** 345 PARK AVENUE SOUTH
- **STREET 2:** 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
- **BUSINESS PHONE:** 646-844-0337

**MAIL ADDRESS:**
- **STREET 1:** 345 PARK AVENUE SOUTH
- **STREET 2:** 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ArTara Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20200110

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PROTEON THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20060420

**As filed with the Securities and Exchange Commission on March 8, 2023**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**Protara Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **20-4580525** |
| (State or other jurisdiction of<br> incorporation or organization) | (I.R.S. Employer<br> Identification No.) |

---

**345 Park Avenue South, Third Floor**

**New York, NY 10010**

(Address of Principal Executive Offices) (Zip Code)

**Amended and Restated 2014 Equity Incentive Plan, as amended**

**2014 Employee Stock Purchase Plan**

(Full title of the plans)

**Jesse Shefferman**

**President and Chief Executive Officer**

**Protara Therapeutics, Inc.**

**345 Park Avenue South, Third Floor**

**New York, NY 10010**

(Name and address of agent for service)

**(646) 844-0337**

(Telephone number, including area code, of agent for service)

***Copies to:***

---

| | |
|:---|:---|
| **Mary J. Grendell, Esq.<br> General Counsel and Corporate Secretary** | **Robert W. Downes**<br> Sullivan & Cromwell LLP |
| Protara Therapeutics, Inc. | 125 Broad St. |
| 345 Park Avenue South, Third Floor | New York, NY 10004 |
| New York, NY 10010 | (212) 558-4000 |
| (646) 844-0337 |  |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**PART I**

**EXPLANATORY NOTE**

Protara Therapeutics, Inc. (the "Registrant") is filing this Registration Statement on Form S-8 (the "Registration Statement") for the purpose of registering an additional 861,933 shares of common stock under the Registrant's Amended and Restated 2014 Equity Incentive Plan, as amended (the "EIP"), and an additional 7,025 shares of common stock under the Registrant's 2014 Employee Stock Purchase Plan (the "ESPP"), pursuant to the "evergreen" provisions of each plan which provide for annual automatic increases in the number of shares of the Registrant's common stock (the "Common Stock") reserved for issuance under each respective plan.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**ITEM 3. Incorporation of Documents by Reference.** 

This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which Registration Statements of the Registrant on Form S-8 relating to the same employee benefit plan are effective. The Registrant previously registered shares of its Common Stock for issuance under the EIP and ESPP under Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the "SEC") on [November 25, 2014](http://www.sec.gov/Archives/edgar/data/1359931/000117184314005694/fs8_112514.htm) (File No. 333-200587), [January 4, 2018](http://www.sec.gov/Archives/edgar/data/1359931/000117184318000173/fs8_010418.htm) (File No. 333-222415), [January 3, 2019](http://www.sec.gov/Archives/edgar/data/1359931/000117184319000095/fs8_010319.htm) (File No. 333-229123), [January 15, 2020](http://www.sec.gov/Archives/edgar/data/1359931/000110465920004017/a20-3439_1s8.htm) (File No. 333-235918), [March 11, 2021](http://www.sec.gov/Archives/edgar/data/1359931/000121390021014711/ea137341-s8_protaratherap.htm) (File No. 333-254124) and [March 9, 2022](http://www.sec.gov/Archives/edgar/data/1359931/000121390022011313/ea156646-s8_protaratherap.htm) (File No. 333-263392). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

The registrant hereby also incorporates by reference into this Registration Statement the following documents previously filed by the registrant with the SEC (other than portions of Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits related to such items or other portions of documents filed with the SEC which were furnished, but not filed, pursuant to applicable rules promulgated by the SEC):

● the Company's Annual Report on Form 10-K filed with the SEC on [March 8, 2023](http://www.sec.gov/ix?doc=/Archives/edgar/data/1359931/000121390023018373/f10k2022_protarathera.htm) ;

● the Company's Current Reports on Form 8-K filed with the SEC on [January 5, 2023](http://www.sec.gov/ix?doc=/Archives/edgar/data/1359931/000121390023001140/ea171261-8k_protara.htm) and [January 30, 2023](http://www.sec.gov/ix?doc=/Archives/edgar/data/1359931/000121390023005811/ea172250-8k_protara.htm) ; and

● the description of the Company's Common Stock contained in Exhibit 4.2 to the Company's Annual Report on Form 10-K filed with the SEC on [March 11, 2021](http://www.sec.gov/Archives/edgar/data/1359931/000121390021014709/f10k2020_protaratherapeutics.htm) , including any amendments or reports filed for the purpose of updating such description.

In addition, all reports and other documents subsequently filed by the registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

**ITEM 8. EXHIBITS.**

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description** |
| 4.1 | [Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed with the SEC on October 27, 2014).](http://www.sec.gov/Archives/edgar/data/1359931/000110465914074038/a14-15225_12ex3d1.htm) |
| 4.2 | [Certificate of Amendment to the Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed with the SEC on January 10, 2020).](http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex3-1.htm) |
| 4.3 | [Second Certificate of Amendment to the Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Registrant's Quarterly Report on Form 10-Q, filed with the SEC on May 13, 2020).](http://www.sec.gov/Archives/edgar/data/1359931/000121390020011893/f10q0320ex3-3_artara.htm) |
| 4.4 | [Second Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K, filed with the SEC on August 3, 2017).](http://www.sec.gov/Archives/edgar/data/1359931/000117184317004634/exh_32.htm) |
| 4.5 | [Certificate of Designation of Preferences, Rights and Limitations of Series 1 Convertible Preferred Stock (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K, filed with the SEC on January 10, 2020).](http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex3-2.htm) |
| 4.6 | [Certificate of Amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series 1 Convertible Non-Voting Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed with the SEC on September 23, 2020).](http://www.sec.gov/Archives/edgar/data/1359931/000121390020027951/ea127215ex3-1_protara.htm) |
| 4.7 | [Registration Rights Agreement, dated as of September 23, 2019, by and among the Registrant and the institutional investors named therein (incorporated by reference to Exhibit 10.5 to the Registrant's Current Report on Form 8-K, filed with the SEC on September 24, 2019).](http://www.sec.gov/Archives/edgar/data/1359931/000104746919005409/a2239754zex-10_5.htm) |
| 4.8 | [Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K, filed with the SEC on January 10, 2020).](http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex4-1.htm) |
| 5.1\* | [Opinion of Sullivan & Cromwell LLP.](ea174828ex5-1_protara.htm) |
| 23.1\* | [Consent of Ernst & Young LLP](ea174828ex23-1_protara.htm) |
| 23.2\* | [Consent of Sullivan & Cromwell LLP (included in Exhibit 5.1).](ea174828ex5-1_protara.htm) |
| 24.1\* | [Power of Attorney (included on signature page).](#poa) |
| 99.1 | [Amended and Restated 2014 Equity Incentive Plan of the Registrant, as amended (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K, filed on January 10, 2020).](http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex10-1.htm) |
| 99.2 | [Forms of Stock Option Agreement, Option Exercise, Restricted Stock Unit Grant and Restricted Stock Unit Agreement under the Amended and Restated 2014 Equity Incentive Plan of the Registrant, as amended (incorporated by reference to Exhibit 10.25 to the Registrant's Annual Report on form 10-K for the fiscal year ended December 31, 2019 filed on March 20, 2020).](http://www.sec.gov/Archives/edgar/data/1359931/000117184320001860/exh_1025.htm) |
| 99.3 | [2014 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.25 to Amendment No. 1 to the Company's Registration Statement on Form S-1 filed on October 7, 2014).](http://www.sec.gov/Archives/edgar/data/1359931/000104746914008146/a2221509zex-10_25.htm) |
| 107\* | [Filing Fee Table](ea174828ex-fee_protara.htm) |

---

\* Filed herewith.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York on March 8, 2023.

---

| | |
|:---|:---|
| **PROTARA THERAPEUTICS, INC.** | **PROTARA THERAPEUTICS, INC.** |
| By: | /s/ Jesse Shefferman |
|  | Jesse Shefferman |
|  | President and Chief Executive Officer |

---

**POWER OF ATTORNEY**

**KNOW ALL PERSONS BY THESE PRESENTS**, that each person whose signature appears below constitutes and appoints Jesse Shefferman, Patrick Fabbio and Mary J. Grendell, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Jesse Shefferman | President and Chief Executive Officer and Director | March 8, 2023 |
| Jesse Shefferman | *(Principal Executive Officer)* |  |
| /s/ Patrick Fabbio | Chief Financial Officer | March 8, 2023 |
| Patrick Fabbio | *(Principal Financial Officer)* |  |
| /s/ Hannah Fry | Vice President, Controller | March 8, 2023 |
| Hannah Fry | *(Principal Accounting Officer)* |  |
| /s/ Luke Beshar | Chairman of the Board of Directors | March 8, 2023 |
| Luke Beshar |  |  |
| /s/ Barry Flannelly, Pharm.D. | Director | March 8, 2023 |
| Barry Flannelly, Pharm.D. |  |  |
| /s/ Roger Garceau, M.D. | Director | March 8, 2023 |
| Roger Garceau, M.D. |  |  |
| /s/ Jane Huang, M.D. | Director | March 8, 2023 |
| Jane Huang, M.D. |  |  |
| /s/ Richard Levy, M.D. | Director | March 8, 2023 |
| Richard Levy, M.D. |  |  |
| /s/ Gregory P. Sargen | Director | March 8, 2023 |
| Gregory P. Sargen |  |  |
| /s/ Cynthia Smith | Director | March 8, 2023 |
| Cynthia Smith |  |  |
| /s/ Michael Solomon, Ph.D. | Director | March 8, 2023 |
| Michael Solomon, Ph.D. |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

[Letterhead of Sullivan & Cromwell LLP]

March 8, 2023

Protara Therapeutics, Inc.,

345 Park Avenue South, Third Floor,

New York, NY 10010.

Ladies and Gentlemen:

In connection with the registration under the Securities Act of 1933 (the "Act") of (i) 861,933 shares of common stock, par value $0.001 per share, of Protara Therapeutics, Inc., a Delaware corporation (the "Company"), issuable under the Company's Amended and Restated 2014 Equity Incentive Plan, as amended (the "EIP") and (ii) 7,025 shares of common stock, par value $0.001 per share, of the Company, issuable under the Company's 2014 Employee Stock Purchase Plan (the "ESPP" and, such shares issuable under the EIP and the ESPP, the "Securities"), we, as your counsel, have examined such corporate records, certificates and other documents, and such questions of law, as we have considered necessary or appropriate for the purposes of this opinion.

Upon the basis of such examination, it is our opinion that when the registration statement relating to the Securities (the "Registration Statement") has become effective under the Act, the terms of the sale of the Securities have been duly established in conformity with the Company's certificate of incorporation and the EIP and the ESPP, and the Securities have been duly issued and sold as contemplated by the Registration Statement and the EIP and the ESPP, the Securities will be validly issued, fully paid and nonassessable.

In rendering the foregoing opinion, we are not passing upon, and assume no responsibility for, any disclosure in any registration statement or any related prospectus or other offering material relating to the offer and sale of the Securities.

The foregoing opinion is limited to the Federal laws of the United States and the General Corporation Law of the State of Delaware, and we are expressing no opinion as to the effect of the laws of any other jurisdiction.

We have relied as to certain factual matters on information obtained from public officials, officers of the Company and other sources believed by us to be responsible.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act.

---

| |
|:---|
| Very truly yours, |
| /s/ Sullivan & Cromwell LLP |

---

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the following Registration Statements:

(1) Registration Statement (Forms S-8 Nos. 333-263392, 333-254124,
333-237497, 333-235918, 333-229123, 333-222415 and 333-200587,) pertaining to the Amended and Restated 2014 Equity Incentive Plan, as
amended and 2014 Employee Stock Purchase Plan of Protara Therapeutics, Inc., and

(2) Registration Statement (Form S-3 No. 333-251224) of Protara
Therapeutics, Inc.;

of our report dated March 8, 2023, with respect to the consolidated financial statements of Protara Therapeutics, Inc. included in this Annual Report (Form 10-K) of Protara Therapeutics, Inc. for the year ended December 31, 2022.

---

| |
|:---|
| /s/ Ernst & Young LLP |
| New York, New York |
| March 8, 2023 |

---

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Table**

<u>Form S-8</u>

(Form Type)

<u>Protara Therapeutics, Inc.</u>

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security<br> Class Title** | **Fee<br> Calculation<br> Rule** | **Amount<br> Registered<sup>(1)</sup>** | **Proposed<br> Maximum<br> Offering<br> Price<br> Per Share** | **Maximum<br> Aggregate<br> Offering<br> Price** | **Fee Rate** | **Amount of<br> Registration Fee<sup>(6)</sup>** |
| Equity | &nbsp;&nbsp;**Amended and Restated 2014 Equity Incentive Plan**<br> Common Stock, $0.001 par value per share<br>| Other | 861933<sup>(2)</sup> | $3.855<sup>(4)</sup> | $3322751.72<sup>(4)</sup> | .0001102 | $366.17 |
| Equity | &nbsp;&nbsp;**2014 Employee Stock Purchase Plan**<br> Common Stock, $0.001 par value per share<br>| Other | 7025<sup>(3)</sup> | $3.855<sup>(5)</sup> | $27081.38<sup>(5)</sup> | .0001102 | $2.98 |
| **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | $3349833.10 |  |  |
| **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** |  |  |  |  |
| **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |  |
| **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $369.15 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Pursuant
to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8
shall also cover any additional shares of Protara Therapeutics, Inc.'s (the "Registrant") common stock, par value $0.001
per share ("Common Stock") that may become issuable under the above-named plans by reason of any stock dividend, stock split,
recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number
of the Registrant's outstanding shares of Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Represents
additional shares of Common Stock reserved for future grant under the Amended and Restated 2014 Equity Incentive Plan, as amended (the
"  ***EIP***") as a result of the automatic increase in shares reserved thereunder on January 1, 2023 pursuant to an
"evergreen" provision contained in the EIP. Pursuant to such provision, the EIP provides that an additional number of shares
will automatically be added annually to the shares authorized for issuance under the EIP on January 1 of each calendar year in an amount
equal to (a) 4% of the total number of shares of the Registrant's Stock (as defined in the EIP) outstanding as of the end of the
immediately preceding fiscal year; or (b) such lesser number of shares of Common Stock as is determined by the Registrant's board
of directors (the "  ***Board***") for the applicable year.

&nbsp;&nbsp;&nbsp;&nbsp;(3) Represents
additional shares of the Registrant's Common Stock reserved for issuance under the 2014 Employee Stock Purchase Plan (the "  ***ESPP*** ")
as a result of the automatic increase in shares reserved thereunder on January 1, 2023 pursuant to an "evergreen" provision
contained in the ESPP. Pursuant to such provision, the ESPP provides that an additional number of shares will automatically be added
annually to the shares authorized for issuance under the ESPP on January 1 of each calendar year, from January 1, 2015 and ending on
(and including) January 1, 2024, in an amount equal to (a) the lesser of (i) 1% of the total number of shares of Common Stock outstanding
as of the end of the immediately preceding fiscal year or (ii) 7,025 shares of Common Stock; or (b) such lesser number of shares of Common
Stock as is determined by the Board for the applicable year.

&nbsp;&nbsp;&nbsp;&nbsp;(4) Estimated
solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and 457(h) of the Securities Act. The
proposed maximum aggregate offering price per share and proposed maximum aggregate offering price are calculated using the average of
the high and low prices of the Common Stock as reported on Nasdaq Capital Market on March 6, 2023.

&nbsp;&nbsp;&nbsp;&nbsp;(5) Estimated
solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and 457(h) of the Securities Act. The
proposed maximum aggregate offering price per share and proposed maximum aggregate offering price are calculated using the average of
the high and low prices of the Common Stock as reported on Nasdaq Capital Market on March 6, 2023, multiplied by 85%, which is the percentage
of the price per share applicable to purchases under the ESPP.

&nbsp;&nbsp;&nbsp;&nbsp;(6) The
Registrant does not have any fee offsets.